CytRx Corporation (CYTR) : During the past 4 weeks, traders have been relatively bearish on CytRx Corporation (CYTR), hence the stock is down -10.28% when compared to the S&P 500 during the same period. However, in the past 1 week, the selling of the stock is down by -5.72% relative to the S&P 500. The 4-week change in the price of the stock is -9.35% and the stock has fallen -5.67% in the past 1 week.
The stock has recorded a 20-day Moving Average of 4.67% and the 50-Day Moving Average is 63.9%. CytRx Corporation (NASDAQ:CYTR): On Fridays trading session , Opening price of the stock was $0.58 with an intraday high of $0.58. The bears continued to sell at higher levels and eventually sold the stock down to an intraday low of $0.565. However, the stock managed to close at $0.5711, a loss of 0.68% for the day. On the previous day, the stock had closed at $0.575. The total traded volume of the day was 705,624 shares.
The company Insiders own 12.4% of CytRx Corporation shares according to the proxy statements. Institutional Investors own 19.77% of CytRx Corporation shares.
CytRx Corporation is a biopharmaceutical research and development company specializing in oncology. The company is focused on the clinical development of aldoxorubicin, its modified version of a chemotherapeutic agent. Aldoxorubicin is a conjugate of the commonly prescribed chemotherapeutic agent doxorubicin that binds to circulating albumin in the bloodstream and is concentrated at the site of tumors. It consists of (6-Maleimidocaproyl) hydrazine, an acid-sensitive molecule that is conjugated to doxorubicin. Its laboratory in Freiburg, Germany is conducting discovery and translational research to create drug candidates that utilize linker technologies that couple chemotherapeutic agents and proteins either inside the body or externally, and then concentrate drug in tumors.